Cover Image
市場調查報告書

流感疫苗的全球市場 (2018年∼2028年):三價流感疫苗 (TIV) 及四價流感疫苗 (QIV)的預測、開發平台分析

Global Influenza Vaccines Market Outlook 2018-2028

出版商 Visiongain Ltd 商品編碼 349913
出版日期 內容資訊 英文 138 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
流感疫苗的全球市場 (2018年∼2028年):三價流感疫苗 (TIV) 及四價流感疫苗 (QIV)的預測、開發平台分析 Global Influenza Vaccines Market Outlook 2018-2028
出版日期: 2018年06月19日 內容資訊: 英文 138 Pages
簡介

2018年的全球流感疫苗的市場,預計記錄35億美元的收益規模。

本報告提供全球流感疫苗的市場調查,市場背景,促進市場成長的產業趨勢,三價疫苗轉移到四價疫苗趨勢,主要的流感疫苗分析、銷售額預測,主要的已開發國家、新興國家市場趨勢分析及市場預測,研發產品線趨勢,SWOT分析,未來展望等資料彙整。

第1章 調查概要

第2章 簡介:全球流感疫苗市場

  • 流感造成的死亡人數
  • 流感的巨大的社會、經濟負擔
  • 流感病毒的年年變異和前一年的疫苗的無效化
  • 流行和全球性流行的發生
  • 流感疫苗市場有影響力的主要企業、組織

第3章 全球流感疫苗市場展望

  • 市場成果
  • 收益預測
  • 產業趨勢、預測
    • 推進需求的趨勢
    • 帶來銷售額的影響的供給效率
    • 資金趨勢
    • 人力資源的保護

第4章 全球流感疫苗市場:各疫苗技術

  • 各疫苗技術的市場預測

第5章 主要流感疫苗

  • Sanofi Pasteur的產品系列:銷售額預測、討論
  • Seqirus的產品系列:銷售額預測、討論
  • GSK的產品系列:銷售額預測、討論
  • AstraZeneca的產品系列:銷售額預測、討論
  • Protein Sciences Company的產品系列:銷售額預測、討論
  • 其他疫苗:銷售額預測、討論

第6章 主要先進國家市場的預測

  • 主要國家的流感疫苗市場成果、預測
  • 美國
  • 日本
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙

第7章 主要新興國家市場預測

  • 主要國家的流感疫苗市場成果、預測
  • 中國
  • 印度
  • 巴西
  • 俄羅斯

第8章 研發產品線

  • 開發中的季節性流感疫苗
    • Sanofi Pasteur
    • Seqirus
    • 武田藥品工業
    • 田邊三菱製藥
  • 開發中的萬能流感疫苗

第9章 定性分析

  • SWOT分析
  • STEP分析

第10章 總論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0318

Title:
Global Influenza Vaccines Market Outlook 2018-2028
Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other.

The latest report from business intelligence provider visiongain offers comprehensive analysis of the global influenza vaccines market. Visiongain assesses that this market will generate revenues of $3.5 billion in 2018.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector. Visiongain's new study tells you and tells you NOW.

In this brand new 138-page report you find 63 in-depth tables, charts and graphs - all unavailable elsewhere.

The report provides clear detailed insight into the global Influenza market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Visiongain's new investigation shows revenue predictions at overall world market, submarket, company, product and national level.

That study gives individual analysis for two influenza vaccine submarkets, which are further divided by vaccine technologies:

  • Trivalent Influenza Vaccines (TIV)
  • Quadrivalent Influenza Vaccines (QIV)

Our new analysis also shows you revenue predictions for the vaccines produced by these five market leaders: and their market share:

  • Sanofi Pasteur
  • GSK
  • Seqirus
  • AstraZeneca
  • Protein Science Corporation.
  • Others

From 2018, large pharmaceutical companies and other biopharma specialists can prosper in that market. See how, discovering organisations' potentials.

Our report analyses the vaccines in research and development and assess their prospects once they enter the market. The R&D pipeline discusses:

  • Seasonal Influenza vaccines in development
  • Universal Influenza vaccines in development

The report includes forecasts to 2028 and analysis of pipeline developments for the following specific vaccines:

  • Fluzone / VaxiGrip
  • Seqirus
  • Fluarix / FluLaval
  • FluMist / Fluenz
  • FluBlok
  • Other

The study shows you prospects for those drug sales in developed and developing regions. There see individual revenue forecasts to 2028 for 11 countries:

  • United States
  • Japan
  • The EU 5 - Germany, France, United Kingdom, Italy and Spain.
  • Brazil, Russia, India and China

Who should read this report?

  • Anyone within the influenza vaccines value chain.
  • Pharmaceutical companies
  • Vaccine manufacturers
  • Healthcare biotech companies
  • Generics and biosimilar producers
  • Drug delivery companies and other technology providers
  • Contract/clinical research organisations (CROs)
  • Pharma contract manufacturers,
  • Pharma/healthcare wholesale and distribution companies
  • Medical device companies
  • Healthcare diagnostics companies
  • R&D specialists
  • Business development managers
  • Marketing managers
  • Technologists
  • Suppliers
  • Investors
  • Banks
  • Government agencies
  • Contractors

Visiongain's study is intended for anyone requiring commercial analyses for the influenza vaccines market and leading companies. You find data, trends and predictions.

Buy our report today Global Influenza Vaccines Market Outlook 2018-2028: Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other. Avoid missing out by staying informed - get our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Influenza Vaccine Market Overview
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Main Questions Answered by This Analytical Study
  • 1.5. Who is This Report For?
  • 1.6. Methods of Research and Analysis
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Associated Company Name Reports
  • 1.9. About Visiongain

2. Introduction to the World Influenza Vaccine Market

  • 2.1 The Influenza Virus Kills over 500,000 People Every Year
  • 2.2. Influenza has a Huge Social and Economic Burden on all Societies
  • 2.3. The Influenza Virus Mutates Annually Rendering the Previous Year's Vaccines Ineffective
    • 2.3.1. All Current Influenza Vaccines are either Trivalent (TIV) or Quadrivalent (QIV)
    • 2.3.2. The Antigenic Drift Mutation Causes Epidemics
    • 2.3.3. The Antigenic Shift Mutation Causes Pandemics
  • 2.4. An Epidemic or a Pandemic Outbreak?
    • 2.4.1. Seasonal Influenza Epidemic (Local)
    • 2.4.2. Pandemic Influenza (Worldwide): ‘A' Subtype
    • 2.4.3. Flu Vaccine Effectiveness
  • 2.5. Key Influencers of the Influenza Vaccine Market
    • 2.5.1. Governments and International Organisations
      • 2.5.1.1. Every Year the World Health Organisation Identifies the Most Likely Strain of the Influenza Virus
      • 2.5.1.2. The Governmental Stance of the Importance of Influenza Directly Drives the Market
      • 2.5.1.3. The WHO's “Influenza Vaccine Production Transfer Project” Affects Big Pharma's Vaccine Sales
    • 2.5.2. Leading Manufacturers
      • 2.5.2.1. Sanofi Pasteur is the Market Leader
      • 2.5.2.2. CSL Has Bought Novartis's Flu Vaccine Business Forming a New Influenza Vaccine Company Seqirus
      • 2.5.2.3. GSK is Now Third Placed in the Market
      • 2.5.2.4. AstraZeneca's Flumist Product is in Trouble

3. Influenza Vaccine World Market Outlook, 2018-2028

  • 3.1. The World Influenza Market Performance, 2017
    • 3.1.1. Growing Elderly Population
    • 3.1.2. Paediatric Influenza Vaccines - High Demand Markets
    • 3.1.3. Emerging Markets
  • 3.2. The World Influenza Market Revenue Forecast for 2018-2028
  • 3.3. The World Influenza Market: Industry Trends, 2018-2028
    • 3.3.1. Demand Driven Trends
    • 3.3.2. Supply Efficiency Affects Sales
    • 3.3.3. Funding Trends
    • 3.3.4. Protecting the Workforce of an Economy
  • 3.4. TIV Vaccines will be Replaced by QIV Vaccines in the Near Future
    • 3.4.1. Trivalent Influenza Vaccines (TIV)
    • 3.4.2. Quadrivalent Influenza Vaccines (QIV)
    • 3.4.3. Influenza Vaccines by TIV and QIV Type

4. Global Influenza Vaccines Market By Vaccine Technology 2018-2028

  • 4.1. The Influenza Vaccine Market Forecast 2018-2028, By Vaccine Technology (Trivalent and Quadrivalent)

5. Leading Influenza Vaccines 2018-2028

  • 5.1. Sanofi Pasteur Influenza Vaccine Portfolio - Sales Forecast and Discussion 2018-2028
  • 5.2. Seqirus Vaccine Portfolio - Sales Forecast and Discussion 2018-2028
  • 5.3. GSK Influenza Vaccine Portfolio - Sales Forecast and Discussion 2018-2028
  • 5.4. AstraZeneca Influenza Vaccine - Sales Forecast and Discussion 2018-2028
  • 5.5. Protein Sciences Company Influenza Vaccine - Sales Forecast and Discussion 2018-2028
  • 5.6. Other Vaccines: Sales Forecast and Discussion 2018-2028

6. Influenza Vaccines in Leading Developed Markets, 2018-2028

  • 6.1. Influenza Vaccines: Leading Markets, 2018, 2023, 2028
    • 6.1.1. Influenza Vaccine: Leading Developed Markets
  • 6.2. The US Vaccine Market: 2018-2028
    • 6.2.1. The US Vaccine Market: 2017
    • 6.2.2. The US Vaccine Market Forecast: 2018-2028
    • 6.2.3. Obama Healthcare Reform - the Benefits for Vaccine Sales
    • 6.2.4. In the US Influenza Vaccines Come Equally from Manufacturers and Distributors
  • 6.3. The Japanese Influenza Vaccine Market 2018-2028
    • 6.3.1. The Japanese Vaccine Market 2017
    • 6.3.2. The Japanese Vaccine Market Forecast 2018-2028
    • 6.3.3. Filing the Vaccine Gap
    • 6.3.4. Kaketsuken Loses Control of the Japanese Vaccine Market
  • 6.4. The United Kingdom Influenza Vaccine Market 2018-2028
    • 6.4.1. The UK Vaccine Market, 2017
    • 6.4.2. The UK Vaccine Market, 2018-2028
    • 6.4.3. Sanofi Pasteur's QIV Vaccine is Authorized for use in the UK
  • 6.5. The German Influenza Vaccine Market: 2018-2028
    • 6.5.1. The German Vaccine Market, 2017
    • 6.5.2. The German Vaccine Market: Forecast 2018-2028
  • 6.6. The French Influenza Vaccine Market 2018-2028
    • 6.6.1. The French Vaccine Market, 2017
    • 6.6.2. The French Vaccine Market: Forecast 2018-2028
    • 6.6.3. French Healthcare System - Events, Policies and Effects
    • 6.6.4. The French Population Have the Highest Doubt over Vaccine Safety in Europe
  • 6.7. The Italian Influenza Vaccine Market: 2018-2028
    • 6.7.1. The Italian Vaccine Market: 2017
    • 6.7.2. The Italian Vaccine Market Forecast: 2018-2028
    • 6.7.3. Uncertain Foundation - Challenges in Public Healthcare
  • 6.8. The Spanish Influenza Vaccine Market 2018-2028
    • 6.8.1. The Spanish Vaccine Market: 2017
    • 6.8.2. The Spanish Vaccine Market Forecast: 2018-2028
    • 6.8.3. District Rules - Economic Challenges

7. Influenza Vaccines in Leading Emerging Markets, 2018-2028

  • 7.1. Influenza Vaccines: Leading Markets, 2018, 2023, 2028
    • 7.1.1. Influenza Vaccine: Leading Emerging National Markets
  • 7.2. The Chinese Influenza Vaccine Market: 2018-2028
    • 7.2.1. The Chinese Influenza Vaccine Market: 2017
    • 7.2.2. The Chinese Influenza Vaccine Market Forecast: 2018-2028
    • 7.2.3. High National Demand for Influenza Vaccines
  • 7.3. The Indian Influenza Vaccine Market: 2018-2028
    • 7.3.1. The Indian Vaccine Market: 2017
    • 7.3.2. The Indian Influenza Vaccine Market Forecast: 2018-2028
    • 7.3.3. Complications of Influenza Vaccines - How Much Progress Possible?
  • 7.4. The Brazilian Influenza Vaccine Market: 2018-2028
    • 7.4.1. The Brazilian Vaccine Market: 2017
    • 7.4.2. The Brazilian Vaccine Market Forecast: 2018-2028
  • 7.5. The Russian Vaccine Market: 2018-2028
    • 7.5.1. The Russian Vaccine Market: 2017
    • 7.5.2. The Russian Vaccine Market Forecast: 2018-2028
    • 7.5.3. Power of the State

8. Research & Development Pipeline for Flu Vaccines

  • 8.1. Seasonal Influenza Vaccines in Development
    • 8.1.1. Sanofi Pasteur
      • 8.1.1.1. Fluzone QIV High Dose
      • 8.1.1.2 VaxiGrip QIV IM (6-35 months)
      • 8.1.1.3 VaxiGrip QIV IM (3 years +)
    • 8.1.2 Seqirus
      • 8.1.2.1. MF59 QIV and TIV Vaccines
    • 8.1.3. Takeda Pharmaceuticals
      • 8.1.3.1. Takeda has Ceased Development of its TAK850 TIV Influenza Vaccine
    • 8.1.4. Mitsubishi Tanabe Pharma
      • 8.1.4.1. Plant Based Virus-Like- Particle Influenza Vaccine
  • 8.2. Universal Influenza Vaccines in Development

9. Qualitative Analysis of the World Influenza Vaccines Industry and Market, 2018- 2028

  • 9.1. SWOT Analysis of the World Influenza Vaccines Industry and Market, 2017
    • 9.1.1. Strengths
      • 9.1.1.1. Ageing Population
      • 9.1.1.2. Influenza Prevention is Crucial
      • 9.1.1.3. Sales Growth in Emerging National Markets
      • 9.1.1.4. Rising Awareness of the Disease
    • 9.1.2. Weaknesses
      • 9.1.2.1. Supply Chain Costs
      • 9.1.2.2. Time Pressure
      • 9.1.2.3. Barriers to Market Entry
    • 9.1.3. Opportunities
      • 9.1.3.1. Strong Research and Development Pipeline
      • 9.1.3.2. Vaccine Delivery - Innovations and Opportunities for Improvements
      • 9.1.3.3. Universal Flu Vaccine
      • 9.1.3.4. Adult Vaccines - High Need
    • 9.1.4. Threats
      • 9.1.4.1. Productivity Gap
  • 9.2. STEP Analysis of the World Influenza Vaccines Industry and Market, 2017
    • 9.2.1. Social Factors
      • 9.2.1.1. Creating a Healthier Society
      • 9.2.1.2. Public Fears of Side-Effects
    • 9.2.2. Technological Forces
      • 9.2.2.1. Advancements in Vaccine Technology
    • 9.2.3. Economic Factors
      • 9.2.3.1. Cost and Time Restraints
      • 9.2.3.2. Emerging Markets Create Demand
    • 9.2.4. Political Factors
      • 9.2.4.1. Influence of Governments

10. Conclusions

  • 10.1. Prevention of Influenza by Use of Flu Shots Rises in Importance
  • 10.2. Japan as a Rising Consumer in the World Influenza Vaccine Market
  • 10.3. Brazil and India Show Robust Growth
  • 10.4. Emergence of a Universal Flu Vaccine
  • 10.5. The US to Retain its Dominance
  • 10.6. Concluding Remarks

Appendix A

  • About Visiongain
  • Associated Reports
  • Report Sales Order Form

Appendix B

  • Report Evaluation Form

Table of Tables

  • Table 1.1: Selected National Vaccines Markets: Revenues ($m) and Market Shares (%) by Leading Country, 2018, 2023 and 2028
  • Table 2.1: Influenza Vaccine Effectiveness (%) 2004/5-2015/6
  • Table 3.1: World Influenza Vaccine Market: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2018-2028
  • Table 3.2: The World Market for Influenza Vaccines by Pharmaceutical Companies and ‘Others'; Revenue Forecast ($m), AGR (%) Market Share (%), 2018- 2028
  • Table 3.3: Influenza Vaccines Divided into TIV and QIV Type, 2017
  • Table 4.1: The Influenza Vaccine Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2018-2028, by Vaccine Technology
  • Table 5.1: Leading Influenza Vaccines: Revenues ($m), 2015
  • Table 5.2: Fluzone/VaxiGrip: Revenue ($m), 2013-2015
  • Table 5.3: Sanofi Pasteur (Fluzone/VaxiGrip); Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2018-2028
  • Table 5.4: Seqirus Influenza Vaccines; Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2018-2028
  • Table 5.5: Fluarix/FluLaval: Revenue ($m), 2013-2015
  • Table 5.6: Fluarix/FluLaval: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2018-2028
  • Table 5.7: FluMist/Fluenz: Revenue ($m), 2013-2015
  • Table 5.8: FluMist/Fluenz: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2018-2028
  • Table 5.9: FluBlok Revenue ($m), 2013-2014
  • Table 5.10: FluBlok: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2018-2028
  • Table 5.11: Other Influenza Vaccines Forecast: ($m), Annual Growth (%), CAGR (%), 2018-2028
  • Table 6.1: Influenza Vaccines Market Revenues ($m) and Market Shares (%) by Leading Country, 2018, 2023 and 2028
  • Table 6.2: The US Influenza Vaccine Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2018-2028
  • Table 6.3: The Japanese Influenza Vaccine Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2018-2028
  • Table 6.4: The UK Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2018-2028
  • Table 6.5: The German Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2018-2028
  • Table 6.6: The French Human Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2018-2028
  • Table 6.7: The Italian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2018-2028
  • Table 6.8: The Spanish Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2018-2028
  • Table 7.1: Human Vaccines Market Revenues ($m) and Market Shares (%) by Leading Country, 2018, 2023 and 2028
  • Table 7.2: The Chinese Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2018-2028
  • Table 7.3: The Indian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2018-2028
  • Table 7.4: The Brazilian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2018-2028
  • Table 7.5: The Russian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2018-2028
  • Table 8.1: Seasonal Influenza Vaccines in Development, 2018
  • Table 8.2: Universal Influenza Vaccines in Development, 2018

Table of Figures

  • Figure 1.1: Influenza Vaccines Market Segmentation
  • Figure 3.1: Influenza Vaccine's Market Share of Global Vaccines Industry (%), 2017
  • Figure 3.2: Growth in the Uptake of Influenza Vaccines, 1990-2015
  • Figure 3.3: Influenza Vaccines: Segmentation by Age (%), 2017
  • Figure 3.4: Influenza Vaccinations by Age, 2016
  • Figure 3.5: Influenza Vaccines: Market Share by Geographical Region, 2017
  • Figure 3.6: The World Market for Influenza Vaccines Divided into Pharma Companies and ‘Others', 2018- 2028
  • Figure 3.7: Influenza Market Share (%) by Pharma Companies and ‘Others': 2018 and 2028
  • Figure 3.8: World Influenza Vaccines Market: Drivers and Restraints, 2018-2028
  • Figure 4.1: The Global Influenza Vaccine Revenue Forecast ($m), 2018-2028, by Vaccine Technology
  • Figure 5.1: Seqirus Influenza Vaccines; Revenue Forecast ($m), 2018-2028
  • Figure 5.2: GSK Influenza Vaccines; Revenue Forecast ($m), 2018-2028
  • Figure 5.3: FluMist/ Fluenz: Revenue Forecast ($m), 2018-2028
  • Figure 5.4: FluBlok: Revenue Forecast ($m), 2018-2028
  • Figure 5.5: Other Influenza Vaccines: Revenue Forecast ($m), 2018-2028
  • Figure 6.1: Influenza Vaccine Market Share (%) by Country, 2018
  • Figure 6.2: Developed National Markets: Drivers and Restraints, 2018-2028
  • Figure 6.3: The US Influenza Vaccine Revenue Forecast ($m), 2018-2028
  • Figure 6.4: The Japanese Influenza Vaccine Revenue Forecast ($m), 2018-2028
  • Figure 6.5: The UK Influenza Vaccines Revenue Forecast ($m), 2018-2028
  • Figure 6.6: The German Influenza Vaccines Revenue Forecast ($m), 2018-2028
  • Figure 6.7: The French Influenza Vaccines Revenue Forecast ($m), 2018-2028
  • Figure 6.8: The Italian Influenza Vaccines Revenue Forecast ($m), 2018-2028
  • Figure 6.9: The Spanish Influenza Vaccines Revenue Forecast ($m), 2018-2028
  • Figure 7.1: Emerging National Markets: Drivers and Restraints, 2018-2028
  • Figure 7.2: The Chinese Influenza Vaccines Revenue Forecast ($m), 2018-2028
  • Figure 7.3: The Indian Influenza Vaccines Revenue Forecast ($m), 2018-2028
  • Figure 7.4: The Brazilian Influenza Vaccines Revenue Forecast ($m), 2018-2028
  • Figure 7.5: The Russian Influenza Vaccines Revenue Forecast ($m), 2018-2028
  • Figure 9.1: SWOT Analysis of the Influenza Vaccines Market, 2017
  • Figure 9.2: STEP Analysis of the Influenza Vaccines Market, 2017

COMPANIES LISTED

  • Advisory Committee for Immunization Practices
  • Astellas Pharmaceuticals
  • AstraZeneca
  • Bharat Immunologicals and Biologicals Corporation Limited
  • Binnopharm
  • Bio Farma
  • bioCSL
  • BioManguinhos/Oswaldo Cruz Foundation
  • BiondVax
  • BiondVax
  • Bionor
  • Biremx
  • Brazilian Ministry of Health
  • Butantan Institute
  • Cabtacuzino Institute
  • Center for Biologics Evaluation and Research
  • Centers for Disease Control and Prevention (CDC)
  • Centre for Disease Control and Prevention
  • Chemo-Sero-Therapeutic Research Institute
  • China National Biotech Group
  • China's National Regulatory Authority
  • Chinese Food and Drug Administration
  • ClearPath
  • CSL
  • CureVac
  • Daiichi Sankyo
  • Developing Countries Vaccine Manufacturers Network (DCVMN)
  • Dynavax
  • Flanders Institute
  • Food and Drug Administration (FDA)
  • FORT
  • Fresenius Pharmaceuticals
  • Gamma Vaccines
  • Gavi Alliance
  • Glaxo Smith Klein
  • GlaxoWellcome
  • Global Influenza Programme
  • Governmental Pharmaceutical Organization (GPO)
  • Green Cross Corporation
  • Grippol
  • Health Service Bureau, Japan
  • Hualan Bio
  • Immune Targeting Systems
  • Indian Association of Paediatrics
  • International Vaccine Access Center (IVAC)
  • Janssen Pharmaceuticals
  • Jenner Institute, University of oxford
  • Johnson & Johnson
  • Krka Pharmaceuticals
  • Medicago
  • Medicare
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • MedImmune
  • Merck
  • Mitsubishi Tanabe Pharma
  • MSD Pharmaceuticals
  • National Health Service, UK
  • Netherlands Vaccine Institute
  • Novartis
  • Organisation for Economic Co-operation and Development
  • Panacea Biotech
  • Partnership for Influenza Vaccine Introduction
  • Petrovax
  • Pfizer
  • Protein Science Corporation
  • Razi Institute
  • Sanofi Pasteur
  • Seqirus
  • Serum Institute of India (SLL)
  • Servizio Sanitario Nationale
  • Shionogi Pharmaceuticals
  • Sinopharm
  • Sistema Unico de Saude
  • SmithKline Beecham
  • Takeda Pharmaceuticals
  • Terumo Pharmaceuticals
  • The Ministry of Health, Labour and Welfare, Japan
  • The Scripps Research Institute
  • Torlak Institut
  • Ultriks
  • US Department of Health and Human Services
  • Vacsera
  • VaxInnate
  • VaxInnate Corporation
  • WHO Strategic Advisory Group of Experts
  • World Health Organization
Back to Top